1613627-45-4

Basic information

• Product Name: 4-(4-chloropiperidin-1-yl)benzonitrile
• Synonyms: 4-(4-chloropiperidin-1-yl)benzonitrile
• CAS NO: 1613627-45-4
• Molecular Weight: 220.702
• Mol File: 1613627-45-4.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-chloropiperidin-1-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-chloropiperidin-1-yl)benzonitrile(1613627-45-4)
• EPA Substance Registry System: 4-(4-chloropiperidin-1-yl)benzonitrile(1613627-45-4)

Safety Data

• Hazardous Substances Data: 1613627-45-4(Hazardous Substances Data)

Upstream product

• 5382-18-3 4-chloro piperidine 
• 1194-02-1 4-fluorobenzonitrile 

Downstream Products

• 1613627-81-8 7-chloro-N-[4-(4-chloropiperidin-1-yl)benzyl]-2-ethylimidazo[1,2-a]pyridine-3-carboxamide 
• 1613627-65-8 C₁₂H₁₇ClN₂ 

Relevant articles and documents

Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives

We report herein the design and synthesis of a series of novel nitrobenzamide derivatives. Results reveal that many of them display considerable in vitro antitubercular activity. Four N-benzyl or N-(pyridine-2-yl)methyl 3,5-dinitrobenzamides A6, A11, C1 and C4 have not only the same excellent MIC values of 1500), opening a new direction for further development.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.